Junshi Biosciences Adds Subsidiary to Lead Key Innovative Drug R&D Projects

Shanghai Junshi Biosciences Co., Ltd. Class H ( (HK:1877) ) has provided an announcement.

Shanghai Junshi Biosciences Co., Ltd. has designated its wholly owned subsidiary Ningbo Junyan Hongshi Biomedical Technology Co., Ltd. as an additional implementing entity for certain sub-projects within its innovative drug R&D investment program, funded by proceeds from a 2022 targeted A-share issuance. The move, approved by the board on 21 April 2026, leaves the total amount and intended use of raised funds unchanged, indicating an internal operational adjustment aimed at optimizing project execution rather than altering capital allocation, and therefore does not require shareholder approval.

This adjustment underscores the company’s efforts to refine its organizational structure to support complex research initiatives while maintaining compliance with capital-raising commitments. By allocating implementation responsibilities to a specialized subsidiary, Junshi Biosciences may enhance project management efficiency and execution capacity in its innovative drug pipeline, which could support its competitive position in China’s rapidly evolving biopharmaceutical sector.

The most recent analyst rating on (HK:1877) stock is a Hold with a HK$34.70 price target. To see the full list of analyst forecasts on Shanghai Junshi Biosciences Co., Ltd. Class H stock, see the HK:1877 Stock Forecast page.

More about Shanghai Junshi Biosciences Co., Ltd. Class H

Shanghai Junshi Biosciences Co., Ltd. is a China-based biopharmaceutical company focused on the research and development of innovative drugs. Listed in both Shanghai and Hong Kong, the company concentrates on advancing cutting-edge biomedical therapies through a portfolio of R&D projects targeting multiple disease areas in domestic and overseas markets.

Average Trading Volume: 3,882,427

Technical Sentiment Signal: Strong Buy

Current Market Cap: HK$45.38B

For a thorough assessment of 1877 stock, go to TipRanks’ Stock Analysis page.